Skip to main content
Erschienen in: Virchows Archiv 3/2016

21.11.2015 | Original Article

TRPM4 protein expression in prostate cancer: a novel tissue biomarker associated with risk of biochemical recurrence following radical prostatectomy

verfasst von: Kasper Drimer Berg, Davide Soldini, Maria Jung, Dimo Dietrich, Carsten Stephan, Klaus Jung, Manfred Dietel, Ben Vainer, Glen Kristiansen

Erschienen in: Virchows Archiv | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Transient receptor potential cation channel, subfamily M, member 4 (TRPM4) messenger RNA (mRNA) has been shown to be upregulated in prostate cancer (PCa) and might be a new promising tissue biomarker. We evaluated TRPM4 protein expression and correlated the expression level with biochemical recurrence (BR) following radical prostatectomy (RP).

Material and methods

The study included 614 patients who had undergone RP. TRPM4 immunohistochemical staining was performed on samples of benign tissue, tissue containing PIN glands and PCa tissue using a commercially available polyclonal antibody. Staining intensity was recorded by two independent observers using a four-tired semi-quantitative grading system (0, 1+, 2+, 3+) converted into H-scores. Interobserver agreement was calculated by linear weighted kappa statistics. The association between staining intensity and BR was analysed using the Kaplan-Meier estimator and uni- and multiple Cox proportional hazard regression models.

Results

Significantly higher staining intensity was found in PCa glands compared to benign glands (p < 0.001). The concordance rate in TRPM4 staining intensities for benign, PIN and PCa tissue ranged from 86.0 to 91.5 %, corresponding to linear weighted kappa values of 0.566–0.789. After adjusting for patient and tumour characteristics, patients with a higher staining intensity in PCa glands compared to matched benign glands and an H-score equal to or above the median had an increased risk of BR (HR 1.79–2.62; p = 0.01–0.03 for the two observers) when compared to patients with a lower staining intensity.

Conclusions

TRPM4 protein expression is widely expressed in benign and cancerous prostate tissue, with highest staining intensities found in PCa. Overexpression of TRPM4 in PCa (combination of high staining intensity and a high H-score) is associated with increased risk of BR after RP.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Malvezzi M, Bertuccio P, Levi F, La VC, Negri E (2014) European cancer mortality predictions for the year 2014. Ann Oncol 25:1650–1656CrossRefPubMed Malvezzi M, Bertuccio P, Levi F, La VC, Negri E (2014) European cancer mortality predictions for the year 2014. Ann Oncol 25:1650–1656CrossRefPubMed
2.
Zurück zum Zitat Rider JR, Sandin F, Andren O, Wiklund P, Hugosson J, Stattin P (2013) Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol 63:88–96CrossRefPubMed Rider JR, Sandin F, Andren O, Wiklund P, Hugosson J, Stattin P (2013) Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol 63:88–96CrossRefPubMed
3.
Zurück zum Zitat Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW (2008) An updated catalog of prostate cancer predictive tools. Cancer 113:3075–3099CrossRefPubMed Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW (2008) An updated catalog of prostate cancer predictive tools. Cancer 113:3075–3099CrossRefPubMed
4.
Zurück zum Zitat Fraser M, Berlin A, Bristow RG, van der Kwast T. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. Urol Oncol 2014 Fraser M, Berlin A, Bristow RG, van der Kwast T. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. Urol Oncol 2014
5.
Zurück zum Zitat Montell C, Birnbaumer L, Flockerzi V, Bindels RJ, Bruford EA, Caterina MJ, Clapham DE, Harteneck C, Heller S, Julius D, Kojima I, Mori Y, Penner R, Prawitt D, Scharenberg AM, Schultz G, Shimizu N, Zhu MX (2002) A unified nomenclature for the superfamily of TRP cation channels. Mol Cell 9:229–231CrossRefPubMed Montell C, Birnbaumer L, Flockerzi V, Bindels RJ, Bruford EA, Caterina MJ, Clapham DE, Harteneck C, Heller S, Julius D, Kojima I, Mori Y, Penner R, Prawitt D, Scharenberg AM, Schultz G, Shimizu N, Zhu MX (2002) A unified nomenclature for the superfamily of TRP cation channels. Mol Cell 9:229–231CrossRefPubMed
7.
Zurück zum Zitat Lehen'kyi V, Prevarskaya N (2011) TRP-Channels and Human Prostate Carcinogenesis. In: Spiess PE (ed) Prostate Cancer - From Bench to Bedside. InTech, Rijeka, pp 133–142 Lehen'kyi V, Prevarskaya N (2011) TRP-Channels and Human Prostate Carcinogenesis. In: Spiess PE (ed) Prostate Cancer - From Bench to Bedside. InTech, Rijeka, pp 133–142
8.
Zurück zum Zitat Thebault S, Flourakis M, Vanoverberghe K, Vandermoere F, Roudbaraki M, Lehen'kyi V, Slomianny C, Beck B, Mariot P, Bonnal JL, Mauroy B, Shuba Y, Capiod T, Skryma R, Prevarskaya N (2006) Differential role of transient receptor potential channels in Ca2+ entry and proliferation of prostate cancer epithelial cells. Cancer Res 66:2038–2047CrossRefPubMed Thebault S, Flourakis M, Vanoverberghe K, Vandermoere F, Roudbaraki M, Lehen'kyi V, Slomianny C, Beck B, Mariot P, Bonnal JL, Mauroy B, Shuba Y, Capiod T, Skryma R, Prevarskaya N (2006) Differential role of transient receptor potential channels in Ca2+ entry and proliferation of prostate cancer epithelial cells. Cancer Res 66:2038–2047CrossRefPubMed
9.
Zurück zum Zitat Vanoverberghe K, Vanden Abeele F, Mariot P, Lepage G, Roudbaraki M, Bonnal JL, Mauroy B, Shuba Y, Skryma R, Prevarskaya N (2004) Ca2+ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells. Cell Death Differ 11:321–330CrossRefPubMed Vanoverberghe K, Vanden Abeele F, Mariot P, Lepage G, Roudbaraki M, Bonnal JL, Mauroy B, Shuba Y, Skryma R, Prevarskaya N (2004) Ca2+ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells. Cell Death Differ 11:321–330CrossRefPubMed
10.
Zurück zum Zitat Zhang L, Barritt GJ (2006) TRPM8 in prostate cancer cells: a potential diagnostic and prognostic marker with a secretory function? Endocr Relat Cancer 13:27–38CrossRefPubMed Zhang L, Barritt GJ (2006) TRPM8 in prostate cancer cells: a potential diagnostic and prognostic marker with a secretory function? Endocr Relat Cancer 13:27–38CrossRefPubMed
11.
Zurück zum Zitat Prevarskaya N, Zhang L, Barritt G (2007) TRP channels in cancer. Biochim Biophys Acta 1772:937–946CrossRefPubMed Prevarskaya N, Zhang L, Barritt G (2007) TRP channels in cancer. Biochim Biophys Acta 1772:937–946CrossRefPubMed
12.
Zurück zum Zitat Mathar I, Jacobs G, Kecskes M, Menigoz A, Philippaert K, Vennekens R (2014) TRPM4. In: Nilius B, Flockerzi V, editors. Transient Receptor Potential Cation Channels - Handbook of Experimental Pharmacology: Springer. p 461-487 Mathar I, Jacobs G, Kecskes M, Menigoz A, Philippaert K, Vennekens R (2014) TRPM4. In: Nilius B, Flockerzi V, editors. Transient Receptor Potential Cation Channels - Handbook of Experimental Pharmacology: Springer. p 461-487
13.
Zurück zum Zitat Fonfria E, Murdock PR, Cusdin FS, Benham CD, Kelsell RE, McNulty S (2006) Tissue distribution profiles of the human TRPM cation channel family. J Recept Signal Transduct Res 26:159–178CrossRefPubMed Fonfria E, Murdock PR, Cusdin FS, Benham CD, Kelsell RE, McNulty S (2006) Tissue distribution profiles of the human TRPM cation channel family. J Recept Signal Transduct Res 26:159–178CrossRefPubMed
14.
Zurück zum Zitat Kristiansen G, Pilarsky C, Wissmann C, Kaiser S, Bruemmendorf T, Roepcke S, Dahl E, Hinzmann B, Specht T, Pervan J, Stephan C, Loening S, Dietel M, Rosenthal A (2005) Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 205:359–376CrossRefPubMed Kristiansen G, Pilarsky C, Wissmann C, Kaiser S, Bruemmendorf T, Roepcke S, Dahl E, Hinzmann B, Specht T, Pervan J, Stephan C, Loening S, Dietel M, Rosenthal A (2005) Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 205:359–376CrossRefPubMed
15.
Zurück zum Zitat Armisen R, Marcelain K, Simon F, Tapia JC, Toro J, Quest AF, Stutzin A (2011) TRPM4 enhances cell proliferation through up-regulation of the beta-catenin signaling pathway. J Cell Physiol 226:103–109CrossRefPubMed Armisen R, Marcelain K, Simon F, Tapia JC, Toro J, Quest AF, Stutzin A (2011) TRPM4 enhances cell proliferation through up-regulation of the beta-catenin signaling pathway. J Cell Physiol 226:103–109CrossRefPubMed
16.
Zurück zum Zitat Kristiansen G, Fritzsche FR, Wassermann K, Jager C, Tolls A, Lein M, Stephan C, Jung K, Pilarsky C, Dietel M, Moch H (2008) GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer 99:939–948CrossRefPubMedPubMedCentral Kristiansen G, Fritzsche FR, Wassermann K, Jager C, Tolls A, Lein M, Stephan C, Jung K, Pilarsky C, Dietel M, Moch H (2008) GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer 99:939–948CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat McClelland RA, Finlay P, Walker KJ, Nicholson D, Robertson JF, Blamey RW, Nicholson RI (1990) Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res 50:3545–3550PubMed McClelland RA, Finlay P, Walker KJ, Nicholson D, Robertson JF, Blamey RW, Nicholson RI (1990) Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res 50:3545–3550PubMed
18.
Zurück zum Zitat Ashida S, Nakagawa H, Katagiri T, Furihata M, Iiizumi M, Anazawa Y, Tsunoda T, Takata R, Kasahara K, Miki T, Fujioka T, Shuin T, Nakamura Y (2004) Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res 64:5963–5972CrossRefPubMed Ashida S, Nakagawa H, Katagiri T, Furihata M, Iiizumi M, Anazawa Y, Tsunoda T, Takata R, Kasahara K, Miki T, Fujioka T, Shuin T, Nakamura Y (2004) Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res 64:5963–5972CrossRefPubMed
19.
Zurück zum Zitat Liu P, Ramachandran S, Ali SM, Scharer CD, Laycock N, Dalton WB, Williams H, Karanam S, Datta MW, Jaye DL, Moreno CS (2006) Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 66:4011–4019CrossRefPubMed Liu P, Ramachandran S, Ali SM, Scharer CD, Laycock N, Dalton WB, Williams H, Karanam S, Datta MW, Jaye DL, Moreno CS (2006) Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 66:4011–4019CrossRefPubMed
20.
Zurück zum Zitat Singh J, Manickam P, Shmoish M, Natik S, Denyer G, Handelsman D, Gong DW, Dong Q (2006) Annotation of androgen dependence to human prostate cancer-associated genes by microarray analysis of mouse prostate. Cancer Lett 237:298–304CrossRefPubMed Singh J, Manickam P, Shmoish M, Natik S, Denyer G, Handelsman D, Gong DW, Dong Q (2006) Annotation of androgen dependence to human prostate cancer-associated genes by microarray analysis of mouse prostate. Cancer Lett 237:298–304CrossRefPubMed
21.
Zurück zum Zitat Launay P, Fleig A, Perraud AL, Scharenberg AM, Penner R, Kinet JP (2002) TRPM4 is a Ca2 + -activated nonselective cation channel mediating cell membrane depolarization. Cell 109:397–407CrossRefPubMed Launay P, Fleig A, Perraud AL, Scharenberg AM, Penner R, Kinet JP (2002) TRPM4 is a Ca2 + -activated nonselective cation channel mediating cell membrane depolarization. Cell 109:397–407CrossRefPubMed
22.
Zurück zum Zitat Nilius B, Prenen J, Droogmans G, Voets T, Vennekens R, Freichel M, Wissenbach U, Flockerzi V (2003) Voltage dependence of the Ca2 + -activated cation channel TRPM4. J Biol Chem 278:30813–30820CrossRefPubMed Nilius B, Prenen J, Droogmans G, Voets T, Vennekens R, Freichel M, Wissenbach U, Flockerzi V (2003) Voltage dependence of the Ca2 + -activated cation channel TRPM4. J Biol Chem 278:30813–30820CrossRefPubMed
23.
Zurück zum Zitat Ullrich ND, Voets T, Prenen J, Vennekens R, Talavera K, Droogmans G, Nilius B (2005) Comparison of functional properties of the Ca2 + -activated cation channels TRPM4 and TRPM5 from mice. Cell Calcium 37:267–278CrossRefPubMed Ullrich ND, Voets T, Prenen J, Vennekens R, Talavera K, Droogmans G, Nilius B (2005) Comparison of functional properties of the Ca2 + -activated cation channels TRPM4 and TRPM5 from mice. Cell Calcium 37:267–278CrossRefPubMed
24.
Zurück zum Zitat Nilius B, Prenen J, Janssens A, Owsianik G, Wang C, Zhu MX, Voets T (2005) The selectivity filter of the cation channel TRPM4. J Biol Chem 280:22899–22906CrossRefPubMed Nilius B, Prenen J, Janssens A, Owsianik G, Wang C, Zhu MX, Voets T (2005) The selectivity filter of the cation channel TRPM4. J Biol Chem 280:22899–22906CrossRefPubMed
25.
Zurück zum Zitat Earley S, Waldron BJ, Brayden JE (2004) Critical role for transient receptor potential channel TRPM4 in myogenic constriction of cerebral arteries. Circ Res 95:922–929CrossRefPubMed Earley S, Waldron BJ, Brayden JE (2004) Critical role for transient receptor potential channel TRPM4 in myogenic constriction of cerebral arteries. Circ Res 95:922–929CrossRefPubMed
26.
Zurück zum Zitat Simard C, Hof T, Keddache Z, Launay P, Guinamard R (2013) The TRPM4 non-selective cation channel contributes to the mammalian atrial action potential. J Mol Cell Cardiol 59:11–19CrossRefPubMed Simard C, Hof T, Keddache Z, Launay P, Guinamard R (2013) The TRPM4 non-selective cation channel contributes to the mammalian atrial action potential. J Mol Cell Cardiol 59:11–19CrossRefPubMed
27.
Zurück zum Zitat Becerra A, Echeverria C, Varela D, Sarmiento D, Armisen R, Nunez-Villena F, Montecinos M, Simon F (2011) Transient receptor potential melastatin 4 inhibition prevents lipopolysaccharide-induced endothelial cell death. Cardiovasc Res 91:677–684CrossRefPubMed Becerra A, Echeverria C, Varela D, Sarmiento D, Armisen R, Nunez-Villena F, Montecinos M, Simon F (2011) Transient receptor potential melastatin 4 inhibition prevents lipopolysaccharide-induced endothelial cell death. Cardiovasc Res 91:677–684CrossRefPubMed
28.
Zurück zum Zitat Suguro M, Tagawa H, Kagami Y, Okamoto M, Ohshima K, Shiku H, Morishima Y, Nakamura S, Seto M (2006) Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature. Cancer Sci 97:868–874CrossRefPubMed Suguro M, Tagawa H, Kagami Y, Okamoto M, Ohshima K, Shiku H, Morishima Y, Nakamura S, Seto M (2006) Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature. Cancer Sci 97:868–874CrossRefPubMed
30.
Zurück zum Zitat Logan CY, Nusse R (2004) The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20:781–810CrossRefPubMed Logan CY, Nusse R (2004) The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20:781–810CrossRefPubMed
31.
Zurück zum Zitat Fuessel S, Sickert D, Meye A, Klenk U, Schmidt U, Schmitz M, Rost AK, Weigle B, Kiessling A, Wirth MP (2003) Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR. Int J Oncol 23:221–228PubMed Fuessel S, Sickert D, Meye A, Klenk U, Schmidt U, Schmitz M, Rost AK, Weigle B, Kiessling A, Wirth MP (2003) Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR. Int J Oncol 23:221–228PubMed
32.
Zurück zum Zitat Kiessling A, Fussel S, Schmitz M, Stevanovic S, Meye A, Weigle B, Klenk U, Wirth MP, Rieber EP (2003) Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8. Prostate 56:270–279CrossRefPubMed Kiessling A, Fussel S, Schmitz M, Stevanovic S, Meye A, Weigle B, Klenk U, Wirth MP, Rieber EP (2003) Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8. Prostate 56:270–279CrossRefPubMed
33.
Zurück zum Zitat Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Stricker PD, Scher HI, Grygiel JJ, Agus DB, Mack DH, Sutherland RL (2003) Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 63:4196–4203PubMed Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Stricker PD, Scher HI, Grygiel JJ, Agus DB, Mack DH, Sutherland RL (2003) Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 63:4196–4203PubMed
34.
Zurück zum Zitat Peng JB, Zhuang L, Berger UV, Adam RM, Williams BJ, Brown EM, Hediger MA, Freeman MR (2001) CaT1 expression correlates with tumor grade in prostate cancer. Biochem Biophys Res Commun 282:729–734CrossRefPubMed Peng JB, Zhuang L, Berger UV, Adam RM, Williams BJ, Brown EM, Hediger MA, Freeman MR (2001) CaT1 expression correlates with tumor grade in prostate cancer. Biochem Biophys Res Commun 282:729–734CrossRefPubMed
35.
Zurück zum Zitat Fixemer T, Wissenbach U, Flockerzi V, Bonkhoff H (2003) Expression of the Ca2 + -selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression. Oncogene 22:7858–7861CrossRefPubMed Fixemer T, Wissenbach U, Flockerzi V, Bonkhoff H (2003) Expression of the Ca2 + -selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression. Oncogene 22:7858–7861CrossRefPubMed
36.
Zurück zum Zitat Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, Walsh PC, Eisenberger MA (2012) The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 109:32–39CrossRefPubMedPubMedCentral Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, Walsh PC, Eisenberger MA (2012) The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 109:32–39CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Tennstedt P, Koster P, Bruchmann A, Mirlacher M, Haese A, Steuber T, Sauter G, Huland H, Graefen M, Schlomm T, Minner S, Simon R (2012) The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers. Int J Oncol 40:261–268PubMed Tennstedt P, Koster P, Bruchmann A, Mirlacher M, Haese A, Steuber T, Sauter G, Huland H, Graefen M, Schlomm T, Minner S, Simon R (2012) The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers. Int J Oncol 40:261–268PubMed
38.
Zurück zum Zitat Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R, Tam L, Munro AF, Dunne B, Bartlett JM (2006) Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 48:787–794CrossRefPubMed Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R, Tam L, Munro AF, Dunne B, Bartlett JM (2006) Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 48:787–794CrossRefPubMed
39.
Zurück zum Zitat Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRefPubMed Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRefPubMed
Metadaten
Titel
TRPM4 protein expression in prostate cancer: a novel tissue biomarker associated with risk of biochemical recurrence following radical prostatectomy
verfasst von
Kasper Drimer Berg
Davide Soldini
Maria Jung
Dimo Dietrich
Carsten Stephan
Klaus Jung
Manfred Dietel
Ben Vainer
Glen Kristiansen
Publikationsdatum
21.11.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 3/2016
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-015-1880-y

Weitere Artikel der Ausgabe 3/2016

Virchows Archiv 3/2016 Zur Ausgabe

Neu im Fachgebiet Pathologie